Boehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
AbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Cutting-edge CacoReady Cell-based Plates with pre-developed Caco-2 cells for in vitro permeability assessment have been a key tool in a
Renal elimination of drugs: The role of kidney transporters A ReadyCell .pdf White Paper – Author: Lourdes Gombau, R&D Director
Novo Nordisk, a global pharmaceutical leader, has set in motion an extensive expansion project for its production facility in Chartres,
Moderna, Inc. has announced positive interim findings from its Phase 1/2 trial of mRNA-1083, an innovative dual-purpose vaccine targeting both
ReadyCell has developed an advanced range of MDCKII Cell-based Plates for In Vitro Drug-transporter Studies in preclinical testing and drug